Search
Search
Elizabeth Yeu, MD
Show Description +
Dr. Elizabeth Yeu, MD, discusses why knowing patients’ inherent risk for developing keratoconus helps her determine whether to consider corneal cross-linking sooner rather than later.
Posted: 11/09/2021
Elizabeth Yeu, MD
Dr. Elizabeth Yeu, MD, discusses why knowing patients’ inherent risk for developing keratoconus helps her determine whether to consider corneal cross-linking sooner rather than later.
Posted: 11/09/2021
Identifying Keratoconus Risk with Genetic Testing
AvaGen™, The Genetic Eye Test in Modern Practice
AvaGen Genetic Test Brochure for ECPs
AvaGen Patient Brochure
How CXL and Genetic Testing Fit Into the Keratoconus Game Plan
Genetic Testing Builds Confidence
Common Questions Patients Ask Genetic Counselors and How to Talk to Them About Testing
How are innovations in genetic testing affecting eyecare?
[Genetics and Eyecare Today] How Genetic Data Can Help Guide Decisions
[Genetics and Eyecare Today] The Role of Genetic Testing and Early Keratoconus Diagnosis
About Avellino
Avellino Lab USA, Inc. is a global leader in gene therapy and molecular diagnostics at the forefront of precision medicine for eye care and beyond. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as gene therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. Avellino is the first privately held, independent company to get an FDA Emergency Use Authorization (EUA).
Visit us online: avellino.com/en/ | avellino.com/en/products/avagen-test/
Follow Avellino
© 2021 Avellino.com All rights reserved.
.00_00_31_24.Still001_1633117824.png?auto=compress,format&w=180)
.00_19_42_06.Still001_1633118071.png?auto=compress,format&w=180)
